REGγ modulates p53 activity by regulating its cellular localization

Journal of Cell Science

Volumn 123, Issue 23, 2010, Pages 4076-4084

  Liu, Jian ^a,b   Yu, Guowu ^c   Zhao, Yanyan ^a   Zhao, Dengpan ^a   Wang, Ying ^a   Wang, Lu ^a   Liu, Jiang ^a,b   Li, Lei ^a   Zeng, Yu ^a   Dang, Yongyan ^a   Wang, Chuangui ^a   Gao, Guang ^d   Long, Weiwen ^b   Lonard, David M ^b   Qiao, Shanlou ^b,e   Tsai, Ming Jer ^b   Zhang, Bianhong ^a   Luo, Honglin ^d   Li, Xiaotao ^a,b  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SICHUAN AGRICULTURAL UNIVERSITY   (China)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CHUBU UNIVERSITY   (Japan)

Author keywords

Cancer; Monoubiquitylation; p53; REG

Indexed keywords

PROTEASOME; PROTEIN MDM2; PROTEIN P53; REG GAMMA PROTEIN; UNCLASSIFIED DRUG; AUTOANTIGEN; KI ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL NUCLEUS; CELL STRESS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEAR EXPORT SIGNAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR XENOGRAFT; UBIQUITINATION; ACTIVE TRANSPORT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; RANDOMIZATION; TUMOR CELL LINE;

MAMMALIA;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; AUTOANTIGENS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN TRANSPORT; RANDOM ALLOCATION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 78649728761     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.067405     Document Type: Article

References (28)

1. Barton, L. F., Runnels, H. A., Schell, T. D., Cho, Y., Gibbons, R., Tevethia, S. S., Deepe, G. S., Jr and Monaco, J. J. (2004). Immune defects in 28-kDa proteasome activator gamma-deficient mice. J. Immunol. 172, 3948-3954.
2. Boutet, S. C., Disatnik, M. H., Chan, L. S., Iori, K. and Rando, T. A. (2007). Regulation of Pax3 by proteasomal degradation of monoubiquitinated protein in skeletal muscle progenitors. Cell 130, 349-362.
3. Brooks, C. L. and Gu, W. (2006). p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307-315.
4. Carter, S., Bischof, O., Dejean, A. and Vousden, K. H. (2007). C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat. Cell Biol. 9, 428-435.
5. Chen, X., Barton, L. F., Chi, Y., Clurman, B. E. and Roberts, J. M. (2007). Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol. Cell 26, 843-852.
6. Freedman, D. A. and Levine, A. J. (1998). Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18, 7288-7293.
7. Green, D. R. and Chipuk, J. E. (2006). p53 and metabolism: Inside the TIGAR. Cell 126, 30-32.
8. Harms, K., Nozell, S. and Chen, X. (2004). The common and distinct target genes of the p53 family transcription factors. Cell. Mol. Life Sci. 61, 822-842.
9. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
10. Honda, R., Tanaka, H. and Yasuda, H. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27.
11. Kawaguchi, Y., Ito, A., Appella, E. and Yao, T. (2006). Charge modification at multiple C-terminal lysine residues regulates p53 oligomerization and its nucleus-cytoplasm trafficking. J. Biol. Chem. 281, 1394-1400.
12. Kubbutat, M. H., Jones, S. N. and Vousden, K. H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
13. Kudo, N., Matsumori, N., Taoka, H., Fujiwara, D., Schreiner, E. P., Wolff, B., Yoshida, M. and Horinouchi, S. (1999). Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. USA 96, 9112-9117.
14. Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R. and Gu, W. (2003). Monoversus polyubiquitination: differential control of p53 fate by Mdm2. Science 302, 1972-1975.
15. Li, X., Lonard, D. M., Jung, S. Y., Malovannaya, A., Feng, Q., Qin, J., Tsai, S. Y., Tsai, M. J. and O'Malley, B. W. (2006). The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell 124, 381-392.
16. Li, X., Amazit, L., Long, W., Lonard, D. M., Monaco, J. J. and O'Malley, B. W. (2007). Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol. Cell 26, 831-842.
17. Lohrum, M. A., Woods, D. B., Ludwig, R. L., Balint, E. and Vousden, K. H. (2001). C-terminal ubiquitination of p53 contributes to nuclear export. Mol. Cell. Biol. 21, 8521-8532.
18. Mao, I., Liu, J., Li, X. and Luo, H. (2008). REGgamma, a proteasome activator and beyond? Cell. Mol. Life Sci. 65, 3971-3980.
19. Murata, S., Kawahara, H., Tohma, S., Yamamoto, K., Kasahara, M., Nabeshima, Y., Tanaka, K. and Chiba, T. (1999). Growth retardation in mice lacking the proteasome activator PA28gamma. J. Biol. Chem. 274, 38211-38215.
20. Nishizaki, M., Sasaki, J., Fang, B., Atkinson, E. N., Minna, J. D., Roth, J. A. and Ji, L. (2004). Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res. 64, 5745-5752.
21. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H. W. et al. (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723.
22. Rodriguez, M. S., Desterro, J. M., Lain, S., Lane, D. P. and Hay, R. T. (2000). Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome- mediated degradation. Mol. Cell. Biol. 20, 8458-8467.
23. Roessler, M., Rollinger, W., Mantovani-Endl, L., Hagmann, M. L., Palme, S., Berndt, P., Engel, A. M., Pfeffer, M., Karl, J., Bodenmuller, H. et al. (2006). Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell Proteomics 5, 2092-2101.
24. Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J. and Wahl, G. M. (1999). A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18, 1660-1672.
25. Toledo, F. and Wahl, G. M. (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6, 909-923.
26. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C. et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848.
27. Zhang, Y., Xiong, Y. and Yarbrough, W. G. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734.
28. Zhang, Z. and Zhang, R. (2008). Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J. 27, 852-864.